CYP19A1 and breast carcinoma: The first polymer therapeutic to combine chemotherapy and endocrine therapy was the HPMA copolymer conjugate carrying both the aromatase inhibitor aminoglutethimide (AGM) and doxorubicin for breast cancer therapy [66], [67].